These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34702746)

  • 41. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
    Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
    J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
    Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fertility-sparing surgery for patients with stage IC2 or IC3 epithelial ovarian carcinoma: any evidence of safety?
    Nasioudis D; Heyward QD; Ko EM; Haggerty AF; Cory L; Giuntoli Ii RL; Kim SH; Latif NA
    Int J Gynecol Cancer; 2022 Feb; 32(2):165-171. PubMed ID: 34952848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative neutrophil/lymphocyte ratio as prognostic factor in epithelial ovarian cancer.
    Vázquez Rojo J; Vázquez Reguera J; Sánchez del Río A
    Rev Colomb Obstet Ginecol; 2024 Mar; 75(1):. PubMed ID: 39013201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
    Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
    JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
    Greer A; Gockley A; Manning-Geist B; Melamed A; Sisodia RC; Berkowitz R; Horowitz N; Del Carmen M; Growdon WB; Worley M
    Int J Gynecol Cancer; 2021 Oct; 31(10):1341-1347. PubMed ID: 34429355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A large-scale multi-institutional study evaluating prognostic aspects of positive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer.
    Yoshihara M; Emoto R; Kitami K; Iyoshi S; Uno K; Mogi K; Tano S; Yoshikawa N; Matsui S; Kajiyama H
    Sci Rep; 2021 Jul; 11(1):15154. PubMed ID: 34312408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Dahm-Kähler P; Holmberg E; Holtenman M; Rådestad AF; Borgfeldt C; Hjerpe E; Marcickiewicz J; Bjurberg M; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E; Stålberg K
    Gynecol Oncol; 2021 Apr; 161(1):244-250. PubMed ID: 33581846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Plett H; Filippova OT; Garbi A; Kommoss S; Rosendahl M; Langstraat C; Phadnis S; Muallem MZ; Baert T; Chi DS; Aletti GD; Taran FA; Ramspott JP; Zivanovic O; du Bois A; Sonoda Y; Gardner G; Traut A; Roche KL; Harter P
    Gynecol Oncol; 2020 Nov; 159(2):434-441. PubMed ID: 32919778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Filippova OT; Tin AL; Alonso J; Vickers AJ; Tew WP; Gardner GJ; Sonoda Y; Roche KL; Zivanovic O; Chi DS; Shahrokni A
    Gynecol Oncol; 2021 Jun; 161(3):687-692. PubMed ID: 33773807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Factors in Patients Undergoing Primary Cytoreductive Surgery for FIGO Stage IIIC Ovarian, Tubal or Peritoneal Cancer.
    Kaban A; Topuz S; Saip P; Sözen H; Salihoğlu Y
    J Obstet Gynaecol Can; 2018 Apr; 40(4):447-453. PubMed ID: 29055648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
    Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
    Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of comprehensive lymphadenectomy for patients with advanced stage ovarian carcinoma and rare histologic sub-types.
    Nasioudis D; Latif NA; Haggerty AF; Giuntoli Ii RL; Kim SH; Ko EM
    Int J Gynecol Cancer; 2021 Aug; 31(8):1132-1136. PubMed ID: 34193526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.
    Kim M; Suh DH; Park JY; Paik ES; Lee S; Eoh KJ; Nam JH; Lee YY; Kim JW; Kim S
    J Gynecol Oncol; 2018 Jul; 29(4):e60. PubMed ID: 29770630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
    Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.